Marshall Wace’s VistaGen Therapeutics VTGN Stock Holding History

Marshall Wace’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-19,973	Closed	-$13.2K	–	3722
2025 Q4	$13.2K	Buy	+19,973	New	+$72.1K	﹤0.01%	2841
2025 Q3	–	Sell	-34,638	Closed	-$69.3K	–	3460
2025 Q2	$69.3K	Buy	+34,638	New	+$78.7K	﹤0.01%	2574
2021 Q2	–	Sell	-35,408	Closed	-$2.26M	–	3130
2021 Q1	$2.26M	Buy	+35,408	New	+$2.36M	0.01%	1263

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace's VTGN Position: Q1 2026 in Review

Marshall Wace sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 19,973 shares — an estimated $13.2K sold.

Marshall Wace first reported a position in VTGN in Q1 2021 and held it in 3 quarters. The position peaked at $2.26M in Q1 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Marshall Wace reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 19,973 VistaGen Therapeutics shares in Q1 2026, an estimated $13.2K.
Marshall Wace first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 3 quarters.
Marshall Wace's VistaGen Therapeutics position peaked at $2.26M in Q1 2021.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.